ProBio Signs Exclusive Global Licensing Deal With AbTis for Cancer Drug Development

PUBT · 2d ago
ProBio Signs Exclusive Global Licensing Deal With AbTis for Cancer Drug Development
  • ProBio signed an exclusive global licensing agreement with AbTis for a discovery-stage oncology antibody asset.
  • AbTis gains exclusive worldwide development and commercialization rights, with plans to develop a next-generation antibody-drug conjugate using its AbClick platform.
  • The agreement includes an upfront payment to ProBio, potential development and commercial milestone payments, and royalties on future sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CL81758) on November 10, 2026, and is solely responsible for the information contained therein.